Anti-tuberculosis 4FDC tablets - Mystery to chemistry

International Journal of Tuberculosis and Lung Disease

Volumn 7, Issue 3, 2003, Pages 205-206

  Dekker, Theo G ^a   Lötter, Antoni P ^a  

^a NORTH WEST UNIVERSITY   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN;

ANTIBIOTIC RESISTANCE; BIOEQUIVALENCE; DRUG DEGRADATION; DRUG FORMULATION; EDITORIAL; HUMAN; PRIORITY JOURNAL; TUBERCULOSIS;

ANTIBIOTICS, ANTITUBERCULAR; ANTITUBERCULAR AGENTS; DRUG COMBINATIONS; DRUG STABILITY; DRUG STORAGE; ETHAMBUTOL; HUMANS; ISONIAZID; PYRAZINAMIDE; RIFAMPIN; TABLETS; TUBERCULOSIS;

EID: 0037346385     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (11)

1. Enarson D A. Conquering tuberculosis: dream or reality? Int J Tuberc Lung Dis 2002; 6: 369-370.
2. World Health Organization. The use of essential drugs. Ninth report of the WHO Expert Committee (including the revised Model List of Essential Drugs). WHO Technical Report Series No. 895. Geneva: WHO, 2000.
3. Stop TB, World Health Organization. Frequently asked questions about the 4-drug fixed-dose combination tablet recommended by the World Health Organization for treating tuberculosis. WHO/CDS/STB/2002.18. Geneva: WHO, September 2002.
4. Blomberg B, Spinaci S, Fourie B, Laing R. The rationale for recommending fixed-dose combination tablets for treatment of tuberculosis. Bull World Health Organ 2001; 79(1): 61-68.
5. Fourie B, Pillai G C, McIlleron H, et al. Establishing the bioequivalence of rifampicin in fixed dose formulations containing isoniazid with or without pyrazinamide and/or ethambutol compared to the single drug reference preparations administered in loose combination: model protocol. WHO/CDS/TB/99.274. Geneva: WHO, 1999.
6. Singh S, Mariappan T T, Sankar R, Sarda N, Singh B. A critical review of the probable reasons for the poor/variable bioavailability of rifampicin from anti-tubercular fixed-dose combination (FDC) products, and the likely solutions to the problem. Int J Pharm 2001; 228: 5-17.
7. Jindal K C, Chaudhary R S, Singla A K, Gangwal S S, Khanna S. Dissolution test method for rifampicin-isoniazid fixed dose formulations. J Pharm Biomed Anal 1994; 12: 493-497.
8. Shishoo C J, Shah S A, Rathod I S, Savale S S, Kotecha J S, Shah P B. Stability of rifampicin in dissolution medium in presence of isoniazid. Int J Pharm 1999; 190: 109-123.
9. Singh S, Mariappan T T, Sharda N, Singh B. Degradation of rifampicin, isoniazid and pyrazinamide from prepared mixtures and marketed single and combination products under acid conditions. Pharm Pharmacol Commun 2000; 6: 491-494.
10. Singh S, Mohan B. A pilot stability study on four-drug fixed-dose combination anti-tuberculosis products. Int J Tuberc Lung Dis 2003; 7: 298-303.
11. United States Pharmacopeial Convention. Rockville, MD: The United States Pharmacopeia 25, 2001: 1534-1535.